Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma

White, Mariah L.; Atwell, Thomas D.; Kurup, A. Nicholas; Schmit, Grant D.; Carter, Rickey E.; Geske, Jennifer R.; Kottschade, Lisa A.; Pulido, José S.; Block, Matthew S.; Jakub, James W.; Callstrom, Matthew R.; Markovic, Svetomir N.

doi:10.1016/j.mayocp.2015.10.025

Cited by 17 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A proportion of patients with restricted metastatic capacity (either 1-3 or 1-5, with/without well-controlled primary lesions) at the moment of diagnosis and clinical staging (socalled oligometastasis) are probably different from those with extensive metastatic disease [10,11]. Support for the hypothesis of oligometastasis was found within studies of surgical resection for liver metastases in case of colorectal cancer, stereotactic body radiotherapy (SBRT) for distant metastases in case of lung cancer and radiofrequency ablation (RFA) for metastases from melanoma [12][13][14][15]. In regards to HCC patients with limited EHM and well-controlled primary tumours, several studies have shown that they can achieve 5-year survival rates of 30-67% following surgical resection [16,17].…”

Section: Introductionmentioning

confidence: 99%

Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results

Sun

Lyu³

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results

Sun

Lyu³

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Current indications include a range of superficial tumors. Historically, ablation therapies have shown results similar to surgical resection in oligometastatic melanoma [248] . Likewise, ECT has proved highly active [95][96][97] and a valuable adjunct to locoregional therapies (isolated limb infusion/perfusion and oncolytic virus therapy) for in-transit disease [146,249,250] .…”

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy of superficial tumors – Current status:

Campana

Miklavčič

Bertino

et al. 2019

Seminars in Oncology

View full text Add to dashboard Cite

“…However, the same adjustments to the IRE field that protects vital structures may also lead to incomplete elimination of tumor cells. As a result, recurrence remains a significant limitation of currently available ablation therapies [29][30][31] with the rate of local tumor control ranging widely from 36 to 97% [11,[32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice

Rojo

Perez

Damasco

et al. 2021

International Journal of Hyperthermia

View full text Add to dashboard Cite

Background: Metastatic prostate cancer in bone is difficult to treat as the tumor cells are relatively resistant to hormonal or chemotherapies when compared to primary prostate cancer. Irreversible electroporation (IRE) is a minimally invasive ablation procedure that has potential applications in the management of prostate cancer in bone. However, a common limitation of IRE is tumor recurrence, which arises from incomplete ablation that allows remaining cancer cells to proliferate. In this study, we combined IRE with radium-223 (Ra-223), a bone-seeking radionuclide that emits short track length alpha particles and thus is associated with reduced damage to the bone marrow and evaluated the impact of the combination treatment on bone-forming prostate cancer tumors. Methods: The antitumor activity of IRE and Ra-223 as single agents and in combination was tested in vitro against three bone morphogenetic protein 4 (BMP4)-expressing prostate cancer cell lines (C4-2B-BMP4, Myc-CaP-BMP4, and TRAMP-C2-BMP4). Similar evaluation was performed in vivo using a bone-forming C4-2B-BMP4 tumor model in nude mice. Results: IRE and Ra-223 as monotherapy inhibited prostate cancer cell proliferation in vitro, and their combination resulted in significant reduction in cell viability compared to monotherapy. In vivo evaluation revealed that IRE with single-dose administration of Ra-233, compared to IRE alone, reduced the rate of tumor recurrence by 40% following initial apparent complete ablation and decreased the rate of proliferation of incompletely ablated tumor as quantified in Ki-67 staining (53.58 ± 16.0% for IRE vs. 20.12 ± 1.63%; for IRE plus Ra-223; p ¼ 0.004). Histological analysis qualitatively showed the enhanced killing of tumor cells adjacent to bone by Ra-223 compared to those treated with IRE alone. Conclusion: IRE in combination with Ra-223, which enhanced the destruction of cancer cells that are adjacent to bone, resulted in reduction of tumor recurrence through improved clearance of proliferative cells in the tumor region.

show abstract

Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma

Cited by 17 publications

References 51 publications

Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results

Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results

Electrochemotherapy of superficial tumors – Current status:

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice

Contact Info

Product

Resources

About